{"version": "https://jsonfeed.org/version/1.1", "title": "Fierce Pharma", "feed_url": "https://www.fiercepharma.com/", "home_page_url": "82", "description": "a feed of the latest articles on our website", "icon": null, "favicon": null, "authors": [{"name": "Unknown", "url": null, "avatar": null}], "language": "en", "expired": null, "hub": null, "items": [{"id": "https://www.fiercepharma.com/0c26542f-3932-416c-b2d6-9035cc9acccb", "url": "https://www.fiercepharma.com/pharma/eha-jj-sharpens-myeloma-edge-talvey-darzalex-faspro-combo-proves-its-worth-earlier-disease", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/eha-jj-sharpens-myeloma-edge-talvey-darzalex-faspro-combo-proves-its-worth-earlier-disease\" hreflang=\"en\">EHA: J&amp;J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage </a>", "content_text": "", "content_html": "J&amp;J's MonumenTAL-3 phase 3 study of bispecific antibody Talvey and Darzalex Faspro in patients with earlier-stage multiple myeloma earned a plenary spot at the 2026 European Hematology Association annual meeting.", "summary": "J&amp;J's MonumenTAL-3 phase 3 study of bispecific antibody Talvey and Darzalex Faspro in patients with earlier-stage multiple myeloma earned a plenary spot at the 2026 European Hematology Association annual meeting.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Zoey Becker"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/d3fda3cc-7d34-4c48-a383-11205d606d54", "url": "https://www.fiercepharma.com/regulatory/cms-proposes-permanent-framework-medicare-drug-price-negotiations", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/regulatory/cms-proposes-permanent-framework-medicare-drug-price-negotiations\" hreflang=\"en\">CMS proposes permanent framework for Medicare drug price negotiations</a>", "content_text": "", "content_html": "The Trump administration is floating a proposal to establish a permanent framework for the Medicare drug price negotiations, as enabled by the Inflation Reduction Act (IRA).", "summary": "The Trump administration is floating a proposal to establish a permanent framework for the Medicare drug price negotiations, as enabled by the Inflation Reduction Act (IRA).", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Heather Landi"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/95fc1f29-4c60-4c4e-85a1-7e3739ee4672", "url": "https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill\" hreflang=\"en\">The Oral GLP-1 Tracker: Novo\u2019s Wegovy keeps gaining ground in obesity market</a>", "content_text": "", "content_html": "Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts\u2019 notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.", "summary": "Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts\u2019 notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Angus Liu, Kevin Dunleavy, Fraiser Kansteiner"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/33a547bf-37f5-4095-8c17-f4b644d0109e", "url": "https://www.fiercepharma.com/pharma/fda-hearing-amgens-tavneos-will-include-findings-independent-review", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-hearing-amgens-tavneos-will-include-findings-independent-review\" hreflang=\"en\">FDA hearing on Amgen's Tavneos will include findings from an independent review</a>", "content_text": "", "content_html": "An independent research firm is reviewing data on Amgen\u2019s Tavneos as the company prepares for a hearing with the FDA which could determine whether the rare disease treatment remains on the market.", "summary": "An independent research firm is reviewing data on Amgen\u2019s Tavneos as the company prepares for a hearing with the FDA which could determine whether the rare disease treatment remains on the market.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Kevin Dunleavy"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/fc5fca71-1b18-4e6f-8acf-743c88d92e81", "url": "https://www.fiercepharma.com/pharma/latest-twist-zepzelca-saga-jazz-and-pharmamar-lung-cancer-drug-fails-phase-3-test", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/latest-twist-zepzelca-saga-jazz-and-pharmamar-lung-cancer-drug-fails-phase-3-test\" hreflang=\"en\">In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test</a>", "content_text": "", "content_html": "The accelerated approval for Jazz Pharmaceuticals\u2019 small cell lung cancer drug Zepzelca may once again be in jeopardy after another phase 3 failure.", "summary": "The accelerated approval for Jazz Pharmaceuticals\u2019 small cell lung cancer drug Zepzelca may once again be in jeopardy after another phase 3 failure.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Angus Liu"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/39cf200b-2bd0-4cd5-889a-1c71e8f5c4fd", "url": "https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026\" hreflang=\"en\">Regulatory tracker: Novo's oral GLP-1 picks up UK approval</a>", "content_text": "", "content_html": "In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.", "summary": "In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Angus Liu, Eric Sagonowsky, Fraiser Kansteiner, Kevin Dunleavy, Zoey Becker"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/8f770daf-a45a-4dd0-9ab7-9b1dac88483f", "url": "https://www.fiercepharma.com/marketing/eli-lilly-biogen-eisai-and-genentech-sponsor-new-lets-talk-alzheimers-podcast", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/marketing/eli-lilly-biogen-eisai-and-genentech-sponsor-new-lets-talk-alzheimers-podcast\" hreflang=\"en\">Lilly, Biogen, Eisai and Genentech sponsor new \u2018Let\u2019s Talk Alzheimer\u2019s\u2019 podcast</a>", "content_text": "", "content_html": "Audio is becoming an increasingly important area of focus in pharma marketing, and now four big drugmakers have become sponsors of a new podcast focused on Alzheimer\u2019s disease.", "summary": "Audio is becoming an increasingly important area of focus in pharma marketing, and now four big drugmakers have become sponsors of a new podcast focused on Alzheimer\u2019s disease.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Ben Adams"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/df014de9-1127-489d-b661-760fafdd32a5", "url": "https://www.fiercepharma.com/pharma/astellas-ceo-5-year-plan-takeda-psoriasis-win-ra-china-bridge-program", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/astellas-ceo-5-year-plan-takeda-psoriasis-win-ra-china-bridge-program\" hreflang=\"en\">Fierce Pharma Asia\u2014Astellas CEO\u2019s 5-year plan; Takeda\u2019s psoriasis win; RA\u2019s China bridge program</a>", "content_text": "", "content_html": "Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. RA Capital is offering China capabilities to its portfolio companies through a one-year-old initiative. And more.", "summary": "Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. RA Capital is offering China capabilities to its portfolio companies through a one-year-old initiative. And more.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Angus Liu"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/6fb12085-7452-4455-b814-26ffc429d6fb", "url": "https://www.fiercepharma.com/pharma/not-simply-saving-cost-inside-astellas-ceo-5-year-strategy-counter-xtandi-patent-cliff", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/not-simply-saving-cost-inside-astellas-ceo-5-year-strategy-counter-xtandi-patent-cliff\" hreflang=\"en\">\u2018Not simply saving cost\u2019: Inside Astellas CEO\u2019s 5-year strategy to counter Xtandi\u2019s patent cliff</a>", "content_text": "", "content_html": "Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, \u201cit\u2019s not simply saving the cost or reducing the headcount.\u201d", "summary": "Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, \u201cit\u2019s not simply saving the cost or reducing the headcount.\u201d", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Angus Liu"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/17125ec9-8715-48b2-afb1-8feb869438c4", "url": "https://www.fiercepharma.com/biotech/genentech-executes-another-round-layoffs-3-vps-axed", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/biotech/genentech-executes-another-round-layoffs-3-vps-axed\" hreflang=\"en\">Genentech executes another round of layoffs, with 3 VPs axed</a>", "content_text": "", "content_html": "Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group. The company did not reveal how many positions are being affected.", "summary": "Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group. The company did not reveal how many positions are being affected.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Kevin Dunleavy"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/dcf37cad-2345-44e1-a2f2-5e162dc945a7", "url": "https://www.fiercepharma.com/ai-and-machine-learning/all-hhs-agencies-saw-ai-use-case-increases-fy-2025-bipartisan-policy-center", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/ai-and-machine-learning/all-hhs-agencies-saw-ai-use-case-increases-fy-2025-bipartisan-policy-center\" hreflang=\"en\">AI use is surging across HHS, jumping 148% at the FDA in 2025,  Bipartisan Policy Center data finds</a>", "content_text": "", "content_html": "There was a big uptick in the use of AI across all HHS agencies in 2025, though analysts note some use cases may \u201creflect new reporting requirements instead of new deployments.\"", "summary": "There was a big uptick in the use of AI across all HHS agencies in 2025, though analysts note some use cases may \u201creflect new reporting requirements instead of new deployments.\"", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Cailey Gleeson"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/8c03d5c0-3713-42d5-9b2b-b1732c88cc93", "url": "https://www.fiercepharma.com/pharma/novo-reports-cybersecurity-breach-tells-clinical-trial-patients-remain-vigilant", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/novo-reports-cybersecurity-breach-tells-clinical-trial-patients-remain-vigilant\" hreflang=\"en\">Novo reports data breach, tells clinical trial patients to 'remain vigilant'</a>", "content_text": "", "content_html": "As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug giant to report a data breach.", "summary": "As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug giant to report a data breach.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Eric Sagonowsky"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/2bae0b7d-ccaa-4310-98e3-e382c0c97d65", "url": "https://www.fiercepharma.com/pharma/joint-initiative-5-eu-countries-calls-unified-approach-pharma-framework-amid-us-drug-pricing", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/joint-initiative-5-eu-countries-calls-unified-approach-pharma-framework-amid-us-drug-pricing\" hreflang=\"en\">Joint initiative of 5 EU countries calls for 'unified approach' to pharma framework amid US drug pricing pressure</a>", "content_text": "", "content_html": "Facing drug pricing pressure from the U.S., Belgium, the Netherlands, Luxembourg, Austria and Ireland stressed the need for \"collaborative efforts across the Union\" in a June 10 statement.", "summary": "Facing drug pricing pressure from the U.S., Belgium, the Netherlands, Luxembourg, Austria and Ireland stressed the need for \"collaborative efforts across the Union\" in a June 10 statement.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Zoey Becker"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/8fdf7530-46f7-4267-b4e2-8acf1cde317d", "url": "https://www.fiercepharma.com/pharma/jj-shows-results-trial-could-lead-rare-disease-expansion-imaavy", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/jj-shows-results-trial-could-lead-rare-disease-expansion-imaavy\" hreflang=\"en\">J&amp;J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win</a>", "content_text": "", "content_html": "Johnson &amp; Johnson has unveiled data from a pivotal phase 2/3 trial which could pave the way for a label expansion for Imaavy to become the first approved treatment for warm autoimmune hemolytic anemia.", "summary": "Johnson &amp; Johnson has unveiled data from a pivotal phase 2/3 trial which could pave the way for a label expansion for Imaavy to become the first approved treatment for warm autoimmune hemolytic anemia.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Kevin Dunleavy"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/611975fa-e433-41c0-a581-009965c8979e", "url": "https://www.fiercepharma.com/marketing/madrigal-takes-giant-inflatable-liver-us-tour-disease-awareness-push", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/marketing/madrigal-takes-giant-inflatable-liver-us-tour-disease-awareness-push\" hreflang=\"en\">Madrigal takes giant inflatable liver on US tour in disease awareness push</a>", "content_text": "", "content_html": "Madrigal Pharmaceuticals has installed a 20-foot-tall, 41-foot-wide inflatable liver in a Philadelphia park to mark Global Fatty Liver Awareness Day.", "summary": "Madrigal Pharmaceuticals has installed a 20-foot-tall, 41-foot-wide inflatable liver in a Philadelphia park to mark Global Fatty Liver Awareness Day.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Nick Paul Taylor"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/3a3cf69d-e642-407d-a523-ba7f6c9716d8", "url": "https://www.fiercepharma.com/marketing/olixir-ny-teams-crohns-colitis-foundation-its-spill-your-guts-campaign", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/marketing/olixir-ny-teams-crohns-colitis-foundation-its-spill-your-guts-campaign\" hreflang=\"en\">Olixir NY teams with Crohn's &amp; Colitis Foundation for \u2018Spill Your Guts\u2019 campaign </a>", "content_text": "", "content_html": "The Crohn's &amp; Colitis Foundation has tapped agency Olixir NY for its new inflammatory bowel disease public service announcement.", "summary": "The Crohn's &amp; Colitis Foundation has tapped agency Olixir NY for its new inflammatory bowel disease public service announcement.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Ben Adams"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/48ce9a30-50d4-43c0-bce1-afd7a22d1c90", "url": "https://www.fiercepharma.com/pharma/if-thats-not-acceleration-i-dont-know-what-novo-nordisk-ceo-doustdar-talks-leadership-new", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/if-thats-not-acceleration-i-dont-know-what-novo-nordisk-ceo-doustdar-talks-leadership-new\" hreflang=\"en\">\u2018I\u2019m a lot more optimistic today\u2019: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO </a>", "content_text": "", "content_html": "Novo Nordisk CEO Mike Doustdar told Fierce in an interview that he always believed the Big Pharma \u201cdid actually need to become more competitive.\u201d", "summary": "Novo Nordisk CEO Mike Doustdar told Fierce in an interview that he always believed the Big Pharma \u201cdid actually need to become more competitive.\u201d", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Fraiser Kansteiner"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/bf6103fe-9b61-4f67-9ade-505235453641", "url": "https://www.fiercepharma.com/biotech/takedas-tyk2-inhibitor-beats-bristol-myers-sotyktu-psoriasis-showdown", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/biotech/takedas-tyk2-inhibitor-beats-bristol-myers-sotyktu-psoriasis-showdown\" hreflang=\"en\">Takeda\u2019s TYK2 inhibitor beats Bristol Myers\u2019 Sotyktu in phase 3 psoriasis showdown</a>", "content_text": "", "content_html": "Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb\u2019s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year.", "summary": "Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb\u2019s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Nick Paul Taylor"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/e82e52c4-3b8a-4859-8df0-b43cae03fef8", "url": "https://www.fiercepharma.com/marketing/eli-lilly-yells-action-authentic-patient-portrayals-tribeca-festival", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/marketing/eli-lilly-yells-action-authentic-patient-portrayals-tribeca-festival\" hreflang=\"en\">Eli Lilly yells \u2018action\u2019 on authentic patient portrayals at Tribeca Festival</a>", "content_text": "", "content_html": "Three short films created through an Eli Lilly-sponsored initiative are premiering at the Tribeca Festival, furthering the drugmaker\u2019s efforts to improve on-screen representations of people with diseases. <br />", "summary": "Three short films created through an Eli Lilly-sponsored initiative are premiering at the Tribeca Festival, furthering the drugmaker\u2019s efforts to improve on-screen representations of people with diseases. <br />", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Nick Paul Taylor"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}, {"id": "https://www.fiercepharma.com/f8cad7af-6a57-4391-986d-a615c79734f7", "url": "https://www.fiercepharma.com/pharma/amid-growing-industry-backlash-germanys-healthcare-reform-plan-pfizer-ceo-bourla-re", "external_url": null, "title": "<a href=\"https://www.fiercepharma.com/pharma/amid-growing-industry-backlash-germanys-healthcare-reform-plan-pfizer-ceo-bourla-re\" hreflang=\"en\">Pfizer CEO Bourla reconsiders German investments as industry takes aim at healthcare reform plan: Reuters </a>", "content_text": "", "content_html": "The CEO voiced his concerns about Germany's new healthcare reform plan in a letter to Chancellor Friedrich Merz, according to reports.", "summary": "The CEO voiced his concerns about Germany's new healthcare reform plan in a letter to Chancellor Friedrich Merz, according to reports.", "image": null, "banner_image": null, "date_published": "2026-06-30T05:33:14Z", "date_modified": "2026-06-30T05:33:14Z", "authors": ["Zoey Becker"], "tags": [], "language": null, "attachments": ["\n                            {\"url\": string, \n                            'mime_type': string, \n                            'title': strinrg,\n                            'size_in_bytes': int,\n                            'duration_in_seconds': int\n                            "]}]}